Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.555 USD | -0.96% | +7.19% | +77.84% |
15/05 | Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial | MT |
15/05 | Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+77.84% | 20Cr | |
+39.01% | 5.09TCr | |
-0.17% | 4.21TCr | |
+49.62% | 4.2TCr | |
-7.20% | 2.92TCr | |
+12.97% | 2.6TCr | |
-22.35% | 1.89TCr | |
+8.34% | 1.32TCr | |
+24.72% | 1.22TCr | |
+29.91% | 1.22TCr |
- Stock Market
- Equities
- ATOS Stock
- News Atossa Therapeutics, Inc.
- Transcript : Atossa Therapeutics, Inc. Presents at LD Micro 500 Virtual Investor Conference, Sep-04-2020 09